Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Tyra Biosciences, Inc. logo

NASDAQ · TYRA

Tyra Biosciences, Inc.

Healthcare · Biotechnology

$21.07

Down-$0.41 (-1.91%)

Updated Nov 1, 2026, 5:19 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.22B
P/E ratio
-12.83
Dividend yield
0.00%
52-week range
$13.35 – $40.65
Volume
625.77K
Avg. volume
330.86K

Price performance · TYRA

TYRA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

TYRA closed at $21.07 after 20 trading sessions, up 0.67% for the selected period.

Last close
$21.07
Period change
+0.67%
Period low
$18.52
Period high
$21.75
Daily close
View OHLC price history
TYRA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$21.18$21.55$20.315$21.07625.77K
Oct 29, 2026$21.92$22.37$21.10$21.48734.9K
Oct 28, 2026$21.31$21.79$21.16$21.75354.87K
Oct 27, 2026$20.45$21.585$20.05$21.52523.03K
Oct 26, 2026$20.76$20.995$20.3075$20.42790.34K
Oct 23, 2026$20.85$20.85$20.09$20.45520.38K
Oct 22, 2026$20.58$21.28$20.22$20.87826.15K
Oct 21, 2026$20.52$20.99$20.13$20.60724.34K
Oct 20, 2026$19.42$20.58$19.35$20.47607.59K
Oct 19, 2026$18.75$19.49$18.49$19.34871.85K
Oct 16, 2026$19.09$19.09$18.26$18.52648.97K
Oct 15, 2026$18.86$19.30$18.76$19.04418.03K
Oct 14, 2026$18.44$18.825$18.25$18.70484K
Oct 13, 2026$19.39$19.60$18.535$18.56469.54K
Oct 12, 2026$19.73$20.03$19.5072$19.60334.41K
Oct 9, 2026$19.93$20.5875$19.73$19.94649.44K
Oct 8, 2026$20.12$20.165$19.50$19.97792.26K
Oct 7, 2026$19.97$20.79$19.795$20.39477.74K
Oct 6, 2026$20.93$20.985$19.60$20.24763.38K
Oct 5, 2026$20.57$21.03$19.9375$20.93614.36K

Latest TYRA news

The latest Smart Investors Daily articles mentioning TYRA.

Stock researchCompany · Overview

TYRA research

Overview

Company profile and research snapshot.

Company profile

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$36.00
Implied upside
—
Analysts
—
TYRA recent ratings
DateFirmRatingTarget
Sep 22, 2026HC Wainwright & Co.Buy—
Sep 22, 2026OppenheimerOutperform—
Sep 10, 2026WedbushOutperform—
Sep 10, 2026HC Wainwright & Co.Buy—
Sep 4, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 17, 2026

Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value

Tyra Biosciences has delivered a 31.8% gain over the past 3 years, yet the recent pullback in the share price raises a practical question for investors who watch fundamentals closely. Is the current market price meaningfully supported by the company’s book value, or has sentiment moved ahead of what the balance sheet can justify? The stock has returned 31.8% over 3 years, which puts real weight on whether the balance sheet can underpin that kind of share price progress. For a clinical stage...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By